Emergent BioSolutions CFO Richard Lindahl to retire Dec 31, 2026; Frank Vargo named interim CFO

Emergent BioSolutions Inc.

Richard S. Lindahl steps down as CFO and principal financial and accounting officer effective December 31, 2026, then serves as senior executive advisor through March 31, 2027 retirement.
Frank Vargo, 43, VP and Treasurer since November 2025, becomes interim CFO and principal financial and accounting officer starting January 1, 2027.
Vargo receives an additional $3,850 per pay period on top of his current $328,000 base salary, effective January 1, 2027; salary, bonus and equity remain commensurate with his prior seniority.
Lindahl will assist with the transition, including preparation and filing of the Form 10-K for the year ending December 31, 2026; his advisor pay is materially consistent with current compensation.
CEO Joe Papa thanked Lindahl for over eight years of service; the transition is tied to Emergent's multi-year transformation plan.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard Lindahl

Chief Financial Officer

EBS · Emergent BioSolutions Inc.

Effective: 2026-12-31
Successor: Frank Vargo
Filed: October 16, 2026, 7:48 AM ET

On October 16, 2026, Emergent BioSolutions Inc. (the “ Company ”) announced that Richard Lindahl, the Company’s Chief Financial Officer, will step down from his role as the Company’s principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027.

Appointed (interim)

Frank Vargo

Interim Chief Financial Officer

EBS · Emergent BioSolutions Inc.

Effective: 2027-01-01
Filed: October 16, 2026, 7:48 AM ET

The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company’s Interim Chief Financial Officer and principal financial and accounting officer beginning on January 1, 2027.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Lindahl departed as Chief Financial Officer at Emergent BioSolutions Inc..

Action: step down
Role: Chief Financial Officer

Exact text from the filing

On October 16, 2026, Emergent BioSolutions Inc. (the “ Company ”) announced that Richard Lindahl, the Company’s Chief Financial Officer, will step down from his role as the Company’s principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.98

Frank Vargo was appointed as Interim Chief Financial Officer at Emergent BioSolutions Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company’s Interim Chief Financial Officer and principal financial and accounting officer beginning on January 1, 2027.

View on SEC.gov

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-26-000098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.